Spearheading a transformation

In the treatment
and management
of chronic diseases

Epitomee medical is a private company developing and commercializing ingestible therapeutic devices,
aimed to tackle some of today’s most prevalent chronic diseases with a self-managed, safer,
kinder to the system and more manageable way.

Management Team

Board of Directors

Michel Habib

Member of the Board

Michel is a seasoned Venture Capitalist and senior executive investing in MedTech & Biotech, expert in value building throughout the whole spectrum of tech companies development, with a track record of successful exits of over 1.5 $Bn.

 

Currently serves as Managing General Partner of ALIVE Israel HealthTech Fund. Serves on the BOD of Innovalve and Beyeonics.

 

Former advisor to CBG Ltd, a multi Billion family office based in London.

 

Former CEO of Hadasit Bio-Holdings (HDST), serves on the BOD of Enlivex (ENLV), Kahr Medical, Minovia, Omnix, Eximore, Xenia Ventures and VLX Incubator, served on the BOD of Meditate (acquired by Olympus), Chairman of Kahr and on the BOD of Cellcure (acquired by Biotime (LCTX)).

 

Former Venture Partner at Agate Medical Investments and Managing General Partner at MaC LP VC Funds, with over $100M under management, with significant exits (Lumenis, MST, Endochoice, Peptron).

 

Former Elron’s BD Director, managing the Medical Devices sector (Medingo, Given, Brainsgate).

 

Established and managed the Israel investment banking activity of ING Barings, served as VP Investment Banking at Cukierman & Co.

 

During the 90’s served as Israel’s Economic Consul in Boston, and as Commercial Attaché to South Korea. As Officer (Academic Reserve, Captain Res.) in the IDF Navy, managed development of advanced Naval and Aerial systems for the Navy’s elite unit.

 

Mr. Habib holds a BsC in Aeronautical Engineering from the Technion. He is a graduate from Israel’s foreign service economic cadet school, member of the Technion Alumni “100 Club” and graduate from the Global Executive Program on Negotiation (PON) at Harvard Law School.

Let’s collaborate